3.237.27.159
dgid:
enl:
npi:0
Infectious Diseases
Trending Topics

Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal

Posted on

In this phase 3, randomized, controlled trial, children in Nepal between 9 months and 16 years of age received either a typhoid conjugate vaccine (TCV) (n =10,005) or a capsular group A meningococcal conjugate vaccine (MenA) (n = 10,014) as a control. Primary outcome was typhoid fever confirmed by blood culture. Typhoid fever occurred in 7 participants who received TCV and 38 who received MenA vaccine (vaccine efficacy, 81.6%; 95% confidence interval, 58.8 to 91.8; P < 0.001).

To read the full article, visit the New England Journal of Medicine.

 

-Advertisement-
Related Articles
CROI 2020 to be Held Virtually Due to COVID-19 Outbreak
Jun 02, 2020
FDA Approves New Antibacterial Drug for Serious Lung Disease Under Novel Pathway
Mar 16, 2020
No Benefit Associated with Tetanus, Diphtheria Booster in Adults
Mar 05, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-